MorphoSys AG reiterated Monjuvi U.S. net product sales guidance for the year 2022. Monjuvi U.S. Net Product Sales expects to be USD 110 million to USD 135 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.3 EUR | +0.45% | +0.98% | +97.94% |
May. 06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.94% | 2.72B | |
+23.00% | 44.96B | |
+1.07% | 42.65B | |
+45.83% | 41.85B | |
-5.31% | 29.04B | |
+11.09% | 26.08B | |
-21.37% | 19.03B | |
+6.38% | 12.75B | |
+28.63% | 12.06B | |
-3.87% | 11.75B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- MorphoSys AG Reiterates Monjuvi U.S. Net Product Sales Guidance for the Year 2022